Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on February 7, 2014, covering events occurring between February 3, 2014, and February 7, 2014. The company is a Delaware corporation focused on pharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Events
- PROSPER Study Publication: On February 3, 2014, the company announced the publication of data from the PROSPER Phase III pivotal trial for Oxtellar XR (oxcarbazepine extended release) in subjects with partial epilepsy refractory. The results are scheduled for publication in the March issue of Acta Neurologica Scandinavica.
- Investor Relations Schedule: On February 7, 2014, the company announced upcoming investor meetings on February 25, 2014, and a business update at an investor conference on February 26, 2014, both to be held in New York, N.Y.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard incorporation of press releases by reference. The primary outlook is tied to the dissemination of clinical trial data and upcoming investor communications.
Investor Verification Checklist
- Verify the full text of the February 3, 2014 press release (Exhibit 99.1) for detailed PROSPER study results.
- Confirm the agenda and access details for the investor meetings and conference scheduled for late February 2014.
- Review the March issue of Acta Neurologica Scandinavica for the peer-reviewed publication of the Oxtellar XR data.